CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 70 enrolled
Drug / intervention
nebivolol +1 moredrug
Likely dose
nebivolol 5 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00829296
NCT00829296Phase 3Completed
CompareCT.gov

The Effects of Nebivolol on Aortic Impedance Parameters in Type 2 Diabetics

University of Chicago·interventional·Posted Jan 27, 2009·Updated Feb 5, 2016

In Brief

A Phase 3 clinical trial evaluating nebivolol and Metoprolol for Hypertension and Diabetes. Completed, enrolled 70 participants across 1 site.

Detailed Summary

The study is being done to see if a drug shown to lower the risk of heart failure is also effective in reducing the stiffness of the arteries.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHypertension, Diabetes
CountriesUnited States
CollaboratorsForest Laboratories

Timeline

Phase 3CompletedFinished
200920102011201220132014201520162017201820192020202120222023202420252026
First PostedJan 27, 2009
Enrollment StartJan 1, 2009
Primary CompletionApr 1, 2012
Study CompletionApr 1, 2013
TodayJul 2, 2026
Enrollment to primary: 3.3 yearsPosted 17.4 years ago

Interventions

nebivololdrug

Starting at dose of 5 mg daily titrated up to max of 40 mg until target BP of 130/80 is reached

Metoprololdrug

Starting at 50 mg daily dose is titrated to max 200 mg until target BP of 130/80 is reached